7-O-malonyl macrolactin A, a new macrolactin antibiotic from Bacillus subtilis active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and a small-colony variant of Burkholderia cepacia.

Antimicrobial Agents and Chemotherapy
Magally Romero-TabarezGabriella Molinari

Abstract

We report here the discovery, isolation, and chemical and preliminary biological characterization of a new antibiotic compound, 7-O-malonyl macrolactin A (MMA), produced by a Bacillus subtilis soil isolate. MMA is a bacteriostatic antibiotic that inhibits a number of multidrug-resistant gram-positive bacterial pathogens, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and a small-colony variant of Burkholderia cepacia. MMA-treated staphylococci and enterococci were pseudomulticellular and exhibited multiple asymmetric initiation points of septum formation, indicating that MMA may inhibit a cell division function.

References

Jun 1, 1989·The Journal of Infectious Diseases·R WilliamsonD M Shlaes
Jul 1, 1997·The Journal of Antimicrobial Chemotherapy·K HiramatsuF C Tenover
Sep 10, 1998·International Journal of Systematic Bacteriology·M M YakimovK N Timmis
Dec 5, 1998·Microbiology and Molecular Biology Reviews : MMBR·P GiesbrechtJ Wecke
May 29, 1999·The American Journal of Medicine·T M Perl
Oct 26, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S HäusslerI Steinmetz
Aug 5, 2000·Journal of Natural Products·C JaruchoktaweechaiP Menasveta
Aug 6, 2000·The Annals of Pharmacotherapy·N E Russell, R E Pachorek
Oct 12, 2000·Clinical Microbiology Reviews·Y CetinkayaC G Mayhall
Dec 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S K Fridkin
Jan 4, 2001·International Journal of Antimicrobial Agents·I Odenholt
Feb 24, 2001·International Journal of Antimicrobial Agents·R BaxJ Verhoef
Jun 19, 2001·Journal of Immunological Methods·L J JonesV L Singer
Jun 28, 2001·The Journal of Antibiotics·T NagaoH Sano
Feb 21, 2002·Journal of the American Chemical Society·Joseph P MarinoFabío C Tucci
Jan 28, 2003·Drug Discovery Today·Peter W TaylorJ Paul Luzio
Feb 5, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ebbing LautenbachNeil O Fishman
Mar 8, 2003·The Journal of Hospital Infection·L S ChaversK B Waites
Apr 11, 2003·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S HäusslerI Steinmetz
Oct 16, 2003·Current Opinion in Pharmacology·Mark C Enright
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Fred C TenoverBülent Bozdogan
Jan 22, 2004·Canadian Journal of Microbiology·Sung-Won ChoiChul Soo Shin
Mar 5, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G A Pankey, L D Sabath
May 15, 2004·Environmental Microbiology·Susanne Häussler

❮ Previous
Next ❯

Citations

Apr 30, 2011·Biotechnology Letters·Estibaliz Sansinenea, Aurelio Ortiz
Mar 16, 2011·Journal of Natural Products·Ahlem HamdacheIsidro G Collado
Jan 27, 2009·The Journal of Antibiotics·Mi-Jin SohnWon-Gon Kim
Mar 8, 2008·Nature Reviews. Drug Discovery·Rowena L Lock, Elizabeth J Harry
Jul 27, 2007·Natural Product Reports·Matthew D LebarBill J Baker
Aug 15, 2013·Marine Drugs·Muhammad Abdul Mojid MondolMohammad Tofazzal Islam
May 16, 2014·Marine Drugs·Muhammad Abdul Mojid Mondol, Hee Jae Shin
Dec 23, 2015·Natural Product Reports·Eric J N Helfrich, Jörn Piel
Sep 3, 2014·Journal of Applied Microbiology·J T FarmerJ B Kaplan
Apr 14, 2016·Natural Product Research·Wei LiYing-Kun Qiu
Nov 28, 2013·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Ji Won JungHee Eun Kang
Mar 7, 2008·Natural Product Research·X L LuK Y Ni
Nov 7, 2017·Journal of Applied Microbiology·K ChakrabortyV K Kizhakkekalam
Sep 26, 2008·Chemistry & Biodiversity·Xiao-Ling LuBing-Hua Jiao
May 14, 2010·Natural Product Reports·Jörn Piel
Aug 30, 2018·Mini Reviews in Medicinal Chemistry·Aurelio Ortiz, Estibaliz Sansinenea
Dec 21, 2019·Applied Microbiology and Biotechnology·Chetan KeswaniEstibaliz Sansinenea
Sep 8, 2016·Standards in Genomic Sciences·Benjamin J SchofieldPhilip Hugenholtz
Dec 6, 2019·Mini Reviews in Medicinal Chemistry·Aurelio Ortiz, Estibaliz Sansinenea
Mar 16, 2019·Frontiers in Microbiology·Simon CaulierJacques Mahillon
Jan 4, 2019·Applied Microbiology and Biotechnology·Snizhana OlishevskaEric Déziel
Apr 26, 2019·Marine Drugs·Tomasz M Karpiński
Dec 1, 2013·Probiotics and Antimicrobial Proteins·Rosa Anna NastroPatrick Fickers
Dec 3, 2016·BMC Complementary and Alternative Medicine·Jing-Jing GuoChao-Dong Qian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.